Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

Next Previous
Trial Profile

A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Northwest Biotherapeutics

    • Most Recent Events

    • 20 Dec 2023 According to a Northwest Biotherapeutics media release, a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax-L for glioblastoma brain cancer.
    • 22 Nov 2023 According to a Northwest Biotherapeutics media release, the company is in about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K.
    • 13 Oct 2023 According to a Northwest Biotherapeutics media release, the company has completed the majority of the MAA and all but one of the key sections of the MAA have been delivered to the publisher. The Company anticipates that the remaining section of the MAA package will be delivered to the publisher within about two weeks after the consultants return. The submission of the MAA to the MHRA would take place between mid and late November.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top